Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

Inclusion Criteria: * Age ≥ 18 years at the time of enrollment. * History of allogeneic hematopoietic stem cell transplantation. * Presence of Epstein-Barr virus (EBV) DNAemia confirmed by quantitative polymerase chain reaction (qPCR) in peripheral blood. * EBV DNAemia persisting or increasing despite standard management, as determined by the investigator. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Adequate organ function as defined by the study protocol. * Ability to understand and willingness to sign written informed consent. Exclusion Criteria: * Diagnosis of EBV-associated lymphoproliferative disorder requiring immediate cytotoxic chemotherapy. * Active, uncontrolled infection other than EBV. * History of severe autoimmune disease requiring systemic immunosuppressive therapy. * Uncontrolled graft-versus-host disease requiring high-dose systemic corticosteroids or other immunosuppressive treatment. * Prior treatment with EBV-specific adoptive T cell therapy within a defined washout period. * Known active malignancy other than EBV-related disease that may interfere with study participation. * Pregnant or breastfeeding women. * Any medical, psychological, or social condition that, in the opinion of the investigator, would interfere with safe participation in the study.